MétaCan
Menu
Back to cohort
Record W4406102071 · doi:10.1002/alz.14186

Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions

2025· editorial· en· W4406102071 on OpenAlexfundaboutno aff
Ozioma C. Okonkwo, Mónica Rivera Mindt, Michael W. Weiner

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typeeditorial
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsnot available
FundersNational Institute on AgingCanadian Institutes of Health ResearchNational Institutes of HealthNestecGenentechIXICOServierUniversity of Wisconsin-MadisonEisaiBuck Institute for Research on AgingPatient-Centered Outcomes Research InstituteFordham UniversityNorthern California Institute for Research and EducationPfizerBiogenBioClinicaUniversity of Southern CaliforniaH. Lundbeck A/SEli Lilly and CompanyBristol-Myers SquibbMeso Scale DiagnosticsAlzheimer's Disease Neuroimaging InitiativeNovartis Pharmaceuticals CorporationAlzheimer's AssociationFoundation for the National Institutes of Health
KeywordsNeuroimagingAlzheimer's Disease Neuroimaging InitiativeData sharingDementiaClinical trialDiseaseMedicinePositron emission tomographyPsychologyNeuroscienceOncologyInternal medicinePathologyAlternative medicine

Abstract

fetched live from OpenAlex

This special issue of Alzheimer's & Dementia celebrates the accomplishments of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project as it approaches its 20th anniversary in 2024, supported by funding from the National Institute on Aging.The earliest origins of ADNI lie in the groundbreaking discovery that antibodies targeting amyloid can remove amyloid beta (Aβ) plaques, sparking the advent of immunotherapy for Alzheimer's disease (AD). 1 At the same time, the importance of imaging and fluid biomarkers, particularly cerebrospinal fluid (CSF), in AD diagnosis gained recognition.ADNI was established in 2004 to validate and optimize biomarkers for AD clinical trials and freely share all the generated data with the scientific community without any restrictions.Since then, ADNI has evolved through five sequential phases incorporating advancements in the field and contributing to significant breakthroughs such as standardizing and validating Aβ and tau positron emission tomography (PET) imaging and CSF biomarkers.2-4 Moreover, ADNI data informed the design of clinical trials for aducanumab, 5 lecanemab, 6 donanemab, 7 solanezumab, 8 verubecestat, 9 crenezumab, 10 and gantenerumab, 11 facilitating the introduction of disease-modifying treatments into clinical practice.ADNI's open data sharing has led to over 6000 peer-reviewed publications, further highlighting the impact of the study.Furthermore, ADNI's approach to conducting longitudinal observational studies and openly sharing data served as a model for similar initiatives globally, leading to the creation of consortia like the Parkinson's Progression Markers Initiative (PPMI), 12 Japanese ADNI, 13 European ADNI, 14 Korean Brain Aging Study (KBASE), 15,16 China ADNI, 17 and South American initiatives.18 The following projects were also modeled on ADNI: the Dominantly Inherited Alzheimer Network (DIAN) studies, 19 Alzheimer's Disease Research Center Consortium for Clarity in Alzheimer's Disease and Related Dementias Research Through Imaging (CLARiTI), 20 Longitudinal Early-Onset Alzheimer's Disease Study (LEADS), 21 Australian Imaging Biomarker & Lifestyle Flagship Study of Ageing (AIBL), 22 Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects Longitudinal Frontotemporal Lobar Degeneration (ALLFTD), 23 Diverse Vascular Contributions to Cognitive Impairment and Dementia (VCID), 24 and Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID).25

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.019
metaresearch head score (Gemma)0.042
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: none
Teacher disagreement score0.019
Threshold uncertainty score0.098

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0190.042
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0050.003
Science and technology studies0.0030.003
Scholarly communication0.0150.013
Open science0.0030.006
Research integrity0.0070.014
Insufficient payload (model declined to judge)0.0180.009

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.047
GPT teacher head0.378
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicAlzheimer's disease research and treatmentsFrench-language works237,207